My Cart

Fluorescent Human Claudin-18.2 Full Length Protein (VLP)

Customer Reviews
Cat. No. / Size
Price
Qty
CL2-HF218-20ug
$620.00
CL2-HF218-100ug
$1235.00
CL2-HF218-500ug
$4305.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    Claudin-18.2, CLDN18, Claudin-18

  • Source

    Fluorescent Human Claudin-18.2 Full Length Protein-VLP (CL2-HF218) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Val 261 (Accession # P56856-2).

    Predicted N-terminus: Met 1

  • Molecular Characterization

    This protein carries a GFP tag.

    *The isotype control of empty/mock VLP (Cat. No. VLP-NF2P4) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Conjugate

    GFP

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 530 nm

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SEC-HPLC

    Claudin-18.2 SEC-HPLC

    The purity of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-HF218) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     Claudin-18.2 ELISA

    Immobilized Fluorescent Human Claudin-18.2 Full Length Protein-VLP (HEK293) (Cat. No. CL2-HF218) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     Claudin-18.2 SPR

    Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-HF218) captured on CM5 Chip via Anti-Claudin-18.2 antibody can bind Anti-Claudin-18.2 antibody with an affinity constant of 0.433 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     Claudin-18.2 FACS

    2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).

    Protocol
  • Identity-DLS

     Claudin-18.2 DLS

    The mean peak Radius of VLP is 65-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Customer Reviews
Writing Reviews

Background

A tight junction protein normally confined to gastric mucosa but exposed on tumor cell surfaces during malignant transformation. It is a premier target in gastric and pancreatic adenocarcinoma, with the monoclonal antibody zolbetuximab demonstrating significant survival benefit in CLDN18.2-positive advanced disease.

Recent Advances

 
Drug Development Progress
  • English Name:

    Claudin-18 splice variant 2

  • Category:

  • Approved Drugs:

    1 Details

  • Drugs in Clinical Trials:

    82 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background